Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1

被引：87
|
作者：
Choi, Michael Y. [1 ]
Widhof, George F., II [1 ]
Wu, Christina C. N. [1 ]
Cui, Bing [1 ]
Lao, Fitzgerald [1 ]
Sadarangani, Anil [1 ,2 ]
Cavagnaro, Joy [3 ]
Prussak, Charles [1 ]
Carson, Dennis A. [1 ]
Jamieson, Catriona [1 ,2 ]
Kipps, Thomas J. [1 ]
机构：
[1] Univ Calif San Diego, Dept Med, Div Hematol Oncol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Div Regenerat Med, La Jolla, CA 92093 USA
[3] Access Bio, Boyce, VA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2015年 / 15卷
基金：
美国国家卫生研究院;
关键词：
AKT; cancer stem cell; Cirmtuzumab; CLL; Wnt receptor; CHRONIC LYMPHOCYTIC-LEUKEMIA; ANTIGEN ROR1; EXPRESSION; RECEPTOR; PSEUDOKINASE; PHENOTYPE; FAMILY; CLL;
D O I：
10.1016/j.clml.2015.02.010
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncoembryonic antigen. Because of its expression on the cell surface of leukemia cells from patients with chronic lymphocytic leukemia (CLL), but not on normal B-cells or other postpartum tissues, ROR1 is an attractive candidate for targeted therapies. UC-961 is a first-in-class humanized monoclonal antibody that binds the extracellular domain of ROR1. In this article we outline some of the preclinical studies leading to an investigational new drug designation, enabling clinical studies in patients with CLL. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码：S167 / S169
页数：3
相关论文
共 50 条
  • [31] Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis
    Gudi, G.
    Gn, S.
    von Gunten, C.
    Back, J.
    Fang, H.
    Salhi, Y.
    Grossman, F.
    Wolff, G.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (05) : S185 - S185
  • [32] First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
    Hojjat-Farsangi, Mohammad
    Moshfegh, Ali
    Daneshmanesh, Amir Hossein
    Vagberg, Jan
    Styrbjorn, Bystrom
    Schultz, Johan
    Olsson, Elisabeth
    Lofberg, Charlotta
    Norstrom, Carina
    Norin, Martin
    Olin, Thomas
    Osterborg, Anders
    Mellstedt, Hakan
    BLOOD, 2015, 126 (23)
  • [33] Humanized 1D10 monoclonal antibody for therapy of B-cell malignancies - Pre-clinical features
    Link, BK
    Tso, J
    Levitt, D
    Hsu, DH
    Klingbeil, C
    Weiner, GJ
    BLOOD, 1998, 92 (10) : 249A - 249A
  • [34] Activity and biophysical properties related to clinical evaluation of a first-in-class EHL ROR1xCD3 T Cell Engager.
    Granger, David
    Bhatt, Shivam
    Henne, Patricia
    Baccaro, Annalisa
    Fernando, Dinusha
    Gore, Jasmine
    Gbajumo, Ephraim
    O'Donovan, Kieran
    Chester, Kerry
    Nathwani, Amit C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] MSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target, LIF
    Sinclair, Angus
    Hallett, Robin
    Giblin, Patricia
    Huber-Ruano, Isabel
    Anido, Judit
    Pandya, Naimish
    Hoffman, Kimberly
    Sala, Ada
    Pascual, Monica
    Chigancas, Vanessa
    Raman, Swetha
    Fransson, Johan
    Julien, Jean-Philippe
    Wasserman, Robert
    Magram, Jeanne
    Seoane, Joan
    CANCER RESEARCH, 2018, 78 (13)
  • [36] Synergistic action of first-in-class anti-tropomyosin compound, ATM-3507 (Anisina) and microtubule targeting inhibitors in pre-clinical models of non-small cell lung cancer (NSCLC)
    Stehn, J.
    Mariana, A.
    Failes, T.
    Ashokakumar, V.
    Eiffe, E.
    Heaton, A.
    Hook, J.
    Sivanandhan, D.
    Arndt, G.
    Gunning, P.
    Brown, D.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S116 - S116
  • [37] A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
    Cassier, P.
    Eberst, L.
    Garin, G.
    Courbebaisse, Y.
    Terret, C.
    Robert, M.
    Frenel, J. -S.
    Depil, S.
    Delord, J. -P.
    Perol, D.
    Ray-Coquard, I. L.
    Bidaux, A. -S.
    Tabone-Eglinger, S.
    Gilles-Afchain, L.
    Treilleux, I.
    Wang, Q.
    Ducarouge, B.
    Mehlen, P.
    Blay, J. -Y.
    Gomez-Roca, C. A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [38] AK130, a first-in-class Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein, elicits potent anti-tumor efficacy in pre-clinical studies
    Min, J.
    Huang, Z.
    Pang, X.
    Zhong, T.
    Jin, C.
    Chen, N.
    Xia, D.
    Zhang, P.
    Wang, Z. M.
    Xia, Y.
    Li, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S762 - S762
  • [39] GM102, a first-in-class monoclonal glyco-engineered antibody (Ab) targeting Anti-Mullerian-Hormone-Receptor II (AMHRII): safety and hints of activity in Granulosa Cell Tumors (GCT)
    Leary, A.
    Ray-coquard, I.
    Delord, J. P.
    Jungels, C.
    Floquet, A.
    Lesoin, A.
    Cassier, P.
    Fabbro, M.
    Kalbacher, E.
    Gomez-Roca, C.
    Coste, A.
    Dumontet, C.
    Meseure, D.
    Farkkila, A.
    Barret, J. M.
    Lemee, F.
    Prost, J. F.
    Tabah-Fisch, I.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E8 - E8
  • [40] PHASE 1 TRIAL OF FIRST-IN-CLASS ANTI-CD96 MONOCLONAL ANTIBODY INHIBITOR, GSK6097608, MONOTHERAPY AND COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY, DOSTARLIMAB, IN ADVANCED SOLID TUMORS
    Hamid, Omid
    Baxter, Dawn
    Easton, Rachael
    Siu, Lilian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A518 - A518
12345